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Ahstraet 
The gp160 envelope glycoprotein of human immunodeficiency virus type-l (HIV-l) is an essential component of current vaccine trials. The glycans 
of gp160, part of which are highly sialylated, have been shown to influence gp160 immunogenicity. Here, using a panel of synthetic V3 peptides, we 
characterized the anti-V3 antibodies generated in rabbits immunized by desialylated recombinant gp160,,. Amino acid residues flanking the GPGR 
tip of V3 were necessary for the recognition by anti-V3 antibodies raised against either the native or desialylated gp160. Both types of antibodies 
reacted to V3 peptides of MN and SF2 strains and with a North American/European V3 consensus peptide, while anti-desialylated gpl60,, antibodies 
reacted in addition to the V3 of CDC4, WMJ2 and NY5 strains. Yet, the V3 peptides did not signiscantly differ in their secondary structure, as 
determined by circular dichroism. The titer and avidity for V3,, of anti-desialylated gp160,, antibodies were significantly lower than those of 
anti-native gp160,, which likely accounts for the inability of anti-desialylated gp160, sera to neutralize HIV-1,Kinduced syncytia. These results 
indicate that V3 immunogenicity may be iduenced by subtle directed changes in the gpl60 glycosylation pattern. 
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1. Introduction 
Much information has been gathered about the func- 
tions of N-linked glycans of human immunodeficiency 
virus type- 1 (HIV- 1) envelope glycoproteins and on their 
possible influence on immune recognition: glycans of 
mature gp120 and gp41 do not play a determinant role 
in virus infectivity (for reviews, see [1,2]) but they con- 
tribute to its antigenicity [3-71. 
Envelope gp120 is composed of interspersed variable 
(V) and conserved (C) regions, some of which are di- 
sulphide-bonded [8]. The V4-C5 domains are considered 
to be involved in gp120 binding to CD4, the HIV recep- 
tor [9]. The V3 loop is not directly involved in the binding 
to CD4, but is likely to play a crucial role in subsequent 
post-binding events that result in virus/cell membrane 
fusion and virus entry into cells [9-l 11. It is also a pri- 
mary determinant of cell tropism [12]. About 35 amino 
acid (aa) residues long, V3 is the site of the principal 
neutralization determinant (PND) [l 1,13-l 51, and anti- 
V3 neutralizing antibodies (NA) appear to protect ani- 
mals against a homologous HIV-l challenge [ 16-191. 
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However, V3 variability [11,14] may represent a major 
obstacle to develop efficacious vaccines based on such 
responsiveness. Yet, most vaccine strategies are attempt- 
ing to elicit strong and broadly reactive NA against V3 
as presented by gp120 or gp160, based on the current 
knowledge of the key aa involved both in V3 biological 
activity and antigenicity [15,20-231. 
An original approach to elicit broadly anti-V3 NA 
would be to modify gp120 overall carbohydrate padding 
in the hope of exposing hidden epitopes or to enhance 
V3 immunogenicity through conformational changes. 
This approach is supported by evidence that glycans may 
modulate the immunological properties of glycoproteins 
[24-261. In most cases, N-linked glycans are not involved 
per se in the antibody response, but they act through 
their own conformation and/or by interacting with the 
peptide backbone, either by epitope masking or by con- 
formational modifications [27]. The negative charges of 
sialic acids are known to play a prominent role in this 
respect [27-281. 
It has recently been shown that the sialic acids pre- 
sented by several glycans of gp120 and gp41 have impor- 
tant effects on their antigenicity: compared with native 
gpl60, selective deglycosylation of gp160 increases the 
antigenicity of some of its regions, e.g. the V2 domain [5], 
and desialylation elicits antibodies in rabbits that recog- 
nize a conserved epitope downstream of the V2 loop of 
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gp120 and that also cross-react with gp140 of HIV-2 
[6,71. 
Here, taking into account that viral gp160 and its 
recombinant counterpart produced in mammalians cells 
have a similar carbohydrate composition [8,29], we in- 
vestigated whether enzymatic removal of sialic acid from 
recombinant gp160 obtained in mammalian cells modi- 
fies the antibody response to V3 of immunized rabbits. 
2. Materials and methods 
2.1. Immunization of the rabbits 
Soluble recombinant gp160 of HIV-l,, produced by mammalian 
BHK21 cells was a gift from Pasteur Merieux Serums et Vaccins (Lyon, 
France). 
Treatment of gpl60 with neuraminidase from Clostridiumperfringens 
(Sigma, St. Louis, MO) was performed under conditions that were 
previously shown to remove sialic acid without detectable side effects 
such as proteolysis or denaturation [6,30]. 
New Zealand White rabbits (2 rabbits/immunogen) were injected 
intradermally with 200 pug of native or neuraminidase-treated gp160 in 
complete Freund’s adjuvant. This procedure was repeated with incom- 
plete Freund’s adjuvant on days 30, 60,90 and 120, as described [6,7l. 
The anti-gp160 sera studied here were obtained one week after the last 
injection. 
2.2. Enzyme-linked immunosorbent assay (ELISA) 
V3 synthetic peptides, derived from the corresponding aa sequence 
of different HIV-l strains (Los Alamos data base) were obtained from 
the Agence Nationale de Recherche sur le SIDA or purchased from 
Neosytem (Strasbourg, France). 
Ninety-six-well microtiter plates (Nunc, Roskilde, Denmark) were 
coated for 2 h at 37°C with 500 @well of peptide in 50 ~1 of PBS, pH 
7.4. After saturation and washing as described [6,7], 50 ~1 of diluted 
serum were added for 2 h at 37°C. Staining was performed with per- 
oxydase-coupled swine anti-rabbit IgG (Dakopatts, Paris, France) as 
reported [6,7]. 
To assess antibody avidity, increasing amounts of peptides were 
preincubated for 1 h at 37°C with the sera before performing the 
ELISA. 
2.3. Circular dichroism (CD) analysis 
Low ultraviolet circular spectroscopies were recovered on a Jobin- 
Yvon spectrophotometer (Longjumeau, France). The instrument was 
calibrated with (+)-lo-camphorsulfonic acid. Spectra were performed 
at 25°C by using a 0.5 mm path-length cell, with a 2-s time constant 
and a 0.5 mn/s scan rate. The peptide concentration was 0.1 mg/ml as 
determined by aa analysis. The spectra were cumulated 5-fold in water 
and 3-fold in 98% 2,2,2 triIluoroethano1 (TFE). Values were automati- 
cally averaged. 
2.4. Syncytia formation assay 
Cells were cultured in RPM1 1640 supplemented with 5% fetal calf 
serum, 1% glutamine, 1% streptomycin-penicillin (G&co, Irvine, Scot- 
land). CEM or C8166 cells (a gift from H. Holmes, P. Tomlinson and 
A. Newberry, MRC-ADP, UK) were chronically infected with HIV- 
1, or HIV-l,,, respectively. 
Infected cells (1 x 104 were incubated for 2 h with various serum 
dilutions in 96-well plates. Uninfected Molt-4 cells (4 x 104) were then 
added in 100 ~1 of culture medium. Syncytia were counted after 18 h 
at 37°C. To demonstrate that syncytium inhibition was essentially due 
to anti-V3 antibodies, sera were preincubated with 10 pg of the appro- 
priate V3 peptide. 
Preimmune sera were used as negative controls. Anti-Leu3a (Becton- 
Dickinson, Mountain View, CA, USA), a neutralizing anti-CD4 mon- 
oclonal antibody, was used at 2.5 &ml as positive control. 
3. Results 
3.1. Mapping of the V3 region recognized by the 
ant ibodies 
We first determined the region of V3 to which anti- 
native (Nl, N2) and anti-desialylated (Dl, D2) gp160 
antibodies reacted. We examined antibody binding to 
overlapping synthetic peptides encompassing V3LAI and 
to their V3,, counterparts, since the V3MN sequence 
appears as more closely related to that of most European 
and North American field isolates [14]. 
The four sera strongly reacted against peptides (302- 
peptides amino acid sequences 
serum ELBA reactivity (OD) 
Nl N2 Dl D2 
V3(LAI) 302.334 
302-324 
307.327 
312.327 
306.320 
306-323 
306-316 
314-330 
31 Q-327 
321-334 
V3(MN) 307-331 
307-325 
307-320 
311-325 
31 Q-331 
CTRPNNNTRKSIRIQRGPGRAFVTIGKIGNMRQA 
TRPNNNTRKSI RI QRGPGRAFVT 
CNTRKSIRIQRGPGRAFVTIGK - 
IRIQRGPGRAFVTIGK 
NNTRKSI RI QRGPGR 
TRKSI RI QRGPGRAFV 
TRKSI RI QRGP 
I QRGPGRAFVT I GKI GN 
GRAFVT I GK 
AFVT I GKI GNMRQA 
- K- - R- H- - - - - - - Y- TKN- I GT I C 
C-K--R-H_ - _---_ Y-TKN 
- 
_ K_ _ R- H_ - _ _ _ _ _ 
R_ H- - _ _ - - - Y- TKN 
--Y-TKN-IGTIC 
2.3 2.4 1.9 2.1 
1.1 0.6 0.6 1.3 
2.4 1.9 1.6 1.9 
0.8 0.3 0.1 0.6 
- - - - 
- - - - 
- - - - 
0.1 - - - 
- - - - 
- - - - 
2.0 1.7 1.0 0.9 
2.3 1.4 1.1 1.0 
- - - - 
- - - - 
- - - - 
Fig. 1. Mapping of the regions of V3 recognized by sera raised against either native (Nl, N2) or desialylated (Dl, D2) gp160W. Sera were diluted 
1 : 100. The coated peptides were derived from either V3LA, or V3wN OD values were obtained at 492 : 620 mn (-) no reactivity: (OD < 0.1). 
Background OD was 0.03 (number of experiments, n = 3). C was added to the original sequence in order to potentially facilitate coupling to a carrier. 
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serum ELISA reactivity (00) 
V3 peptldes amino acid sequences %/Lai Nl N2 Dl D2 
Lai(307-327) CNTRKSIRIQRGPGRAFVTIGK 100 2.4 2.4 1.4 2.4 
HXB2 _ _ _ _ _ R________________ 95 1.8 1.5 1.4 1.4 
SF2 _ _ _ _ _ - _ Y- ____ _-H-T-R 71 1.9 0.9 0.9 0.8 
ruw _ _ K_ _ R_ H_ - _ _ - _ _ Y-TKN 57 2.3 1.4 1.1 0.9 
Cons _ _ _ _ _ _ _ H_ _ _ _ _ _ _ y_ TGE 88 1.7 0.9 0.8 1.5 
WMJ2 _ _,,_ R_ ,_S_ _ _ _ _ _ _ R_ RE 55 _ 1.2 1.2 
NY5 _ _ _ K-G-A- ----TLYARE- 48 _ _ 0.9 0.8 
CDC4 - H- - - RVTL - - - - VWY- T- E 42 I 0.9 0.9 
SC 
RF 
28 
ELI 
22 
_ - _ TR__ H_ __ _ - _ _ YAT_D 57 I I I I 
_ _ _ _ _ _ _ TK -- --VI YAT-Q 52 I I I 
_ - _ _ Q- TP- GL- QALYTTRGRTK 29 I I 
_ - _ _ QRTP- GL- QSLYTTRSRS 24 I _ 
- - I - QRTS- GL- QALYTTKTRS 19 I I I 
Fig. 2. Reactivity of sera raised against either native (Nl, N2) or desialylated (Dl, D2) gp160 LAI to V3 peptides from different HIV-l strains. 
Conditions are as in Fig. 1. %/Lai: % of homology between the LA1 and the other PND sequences. 
334) and (307-327) of V3rAI, and also against (302-324) 
(Fig. 1). Weak or no reactivity was noted against peptide 
(312-327). Because the sera did not bind to peptides 
(306320), (308-323) and (314330), aa residues flanking 
the conserved GPGR sequence should be important for 
antibody recognition. This corresponds to what is al- 
ready known regarding the PND region [11,20,22,31]. 
With respect to V3,,, the sera reacted also against 
peptides (307-331) and (307-325), but not against pep- 
tides (307-320), 3 1 l-325) and (3 19-331). 
3.2. Reactivity of the sera against V3 peptides from 
d$ferent HIV-l isolates 
To examine whether desialylation of gp160LAI modi- 
fied the immunogenicity of its V3 domain, we compared 
the reactivity of anti-native and anti-desialylated 
g~l60,i antibodies against peptides mimicking the core 
of V3 (corresponding to the 307-327 aa sequence of 
V3,,) of clone HXB2 and of different HIV-l strains 
known to be more or less homologous to HIV-l,,,: 
namely MN, SF2, WMJ2, CDC4, NY5, SC, RF, Z2,26, 
ELI. We also used a peptide derived from the North 
American/European consensus (Cons) sequence [14]. Be- 
side the expected reactivity to V3HXB2, three reactivity 
patterns could also be distinguished (Fig. 2). 
(i) Peptides derived from MN, Cons and SF2 V3 se- 
quences, the homology of which with V3rAI is about 
60-70%, were efficiently recognized by all four sera. 
(ii) Only sera Dl and D2 reacted in addition with V3 
peptides derived from WMJ2, NY5 and CDC4, which 
present 42-55% homology with V3,,. 
(iii) The third group of peptides (SC, RF, 22, 26 and 
ELI) did not react with any of the sera, even though SC 
and RF were, respectively, 57% and 52% homologous to 
V3rA, while the level of homology to V3, of the three 
other peptides was 19-29%. 
As controls, it was verified that the four immune sera 
strongly reacted against a peptide corresponding to gp41 
conserved immunodominant epitope and that the preim- 
mune sera did not react to V3 nor to the gp41 peptide 
(data not shown; [7]). 
3.3. CD analysis of the V3 peptides 
We then examined whether the pattern of antibody 
reactivity observed could be accounted for by the degree 
of homology of the peptides’ secondary structure, as 
determined by CD analysis. The intensive negative band 
around 200 mn noted for all peptides in aqueous solution 
(Fig. 3A, and data not shown) indicated the predomi- 
nance of nonperiodic (unordered) conformer popula- 
tions [32]. When spectra were obtained in TFE, a mem- 
brane-like environment, all peptides exhibited a modified 
shape indicating that they tended to adopt a helix confor- 
mation characterized by typical double minima near 208 
nm and 222 nm and increase of positive ellipticity below 
200 mn (Fig. 3B, and data not shown). An intense nega- 
tive band was shown by the peptides from 22, 26, and 
ELI (data not shown). 
3.4. Inhibition of syncytium formation by the sera 
We have previously shown that rabbit antisera to both 
native (Nl, N2) or desialylated (Dl, D2) gp16O,*i neu- 
tralize HIV- 1 LAI- induced syncytia and infection to the 
same extent [6]. Because these sera reacted with V3MN as 
well as with V3LAI in ELISA, we tested whether they 
could also inhibit HIV-l,,-induced syncytia. 
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----.---I- RF 
d” * 
Fig. 3. Circular dichroism spectra of V3 peptides in water (A) and in 98% TFE (B). AE corresponds to the variation of molar aa residue absorption 
coefficient expressed in M-‘cm-‘. 
As reported, all sera neutralized syncytia induced by 
HIV-lLAI [6] but only Nl and N2, and not Dl and D2, 
inhibited HIV-l,,- mediated syncytia in a dose-depend- 
ent manner (Fig. 4). Preincubation of Nl (and N2; data 
not shown) with V3MN peptide (307-325) abolished the 
serum capability to inhibit HIV-l,, syncytia. Therefore, 
this inhibitory effect was mainly due to anti-V3 antibod- 
ies. 
As controls, it was shown that anti-Leu3a antibodies 
neutralized syncytia and that preimmune sera had no 
effect. 
Sample 
Nl 
N2 
Dl 
D2 
Nl+V3MN 
Anti-Leu3a 
serum dilution 
1110 1130 11100 
X xx - 
X xx xxx 
xxx xxxx xxxx 
xxxx xxxx xxxx 
xxx xxxx xxxx 
Prelmmune xxxx xxxx xxxx 
Fig. 4. Ability of sera raised against either native (Nl, N2) or desialyl- 
ated (Dl, D2) gp160, to inhibit HIV-l,- or HIV-l,,-mediated 
syncytia. HIV-lr,,n infected C8166 cells (1 x 10-’ cells) were incubated 
in microtiter plates with different serum dilutions for 2 h before the 
addition of Molt-4 cells (4 x 1 O4 cells). Syncytia were scored after 18 h. 
Syncytium inhibition relative to the control (preimmune sera or no 
serum) was scored as follows: - = 98% reduction of syncytia; + = 90- 
98% reduction; ++ = 6@90% reduction; +++ = 2&60% reduction; 
++++ = c 20% reduction. Preincubation of V3,, pcptide (10 ,~g) with 
Nl (Nl + V3MN) before adding C8166 cells and co-incubation of 
Leu3a monoclonal antibody (Leu3a) with infected C8166 cells and 
Molt-4 cells were also performed. 
3.5, Characterization of the cross reactive anti-V3 
antibodies 
Inhibition of HIV-l,,-mediated syncytia by Nl and 
N2 correlated with their ability to bind to V3MN in 
ELISA but discrepant results were obtained in this re- 
spect with Dl and D2, which were unable to block HIV- 
1 -induced fusion though they bound also to V3,, 
pF;tides. This different behaviour may be due either to 
differences in the amounts of V3,, cross-reacting anti- 
bodies or to differences in the affinity of the antibodies 
for the peptides. 
ELISA titration experiments (Fig. 5A) showed that 
the four sera recognized V3m (307-325) in a dose-de- 
pendent manner, but with different titers. For example, 
if the titer is defmed as the serum dilution which results 
in a 1 OD value, titers were significantly higher for Nl 
and N2 than for Dl and D2 sera (1 x 10e3 and 3 x 10m4 
vs. 1 x lo-*), respectively. 
The avidity for V3 MN of the corresponding antibodies 
was also examined (Fig. 5B). The concentration of solu- 
ble V3MN peptide that inhibited by 50% (K,,,) Nl and N2 
antibody binding to the same coated peptide was in the 
3 x 10e7 M range, while it was about 1 x 10m5 M for Dl 
and D2. 
Comparatively, the four sera recognized V3rAI to the 
same extent, 1 OD values being noted with sera diluted 
1 x 10e3 to 3 x 10e4, and antibodies in these sera had a 
similarity high avidity for the peptide (X& from 5 x 10m7 
to 1 x 10e6 M; data not shown). 
Therefore, both the titer and the avidity of Dl and D2 
antibodies for V3MN may be considered as lower than 
those of Nl and N2 antibodies. 
These characteristics were also determined with V3 
peptides of WMJ2, NY5 and CDC4, which were recog- 
nized only by Dl and D2. The titers of Dl and D2 (data 
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2 
8 
-6 -5 -4 -3 -2 -1 
5A 
+ Ni 
--f N2 
--o- Dl 
* D2 
log serum dilution 
-9 -8 -7 -6 -5 -4 
log[peptide] M 
Fig. 5. Determination of the titer (A) and avidity (B) to V3m peptide 
(307-325) of sera raised against either native (NJ, N2) or desialylated 
@l, D2) g~160,. The diluted sera were added to V3r_c+zoated plates 
(A). Different amounts of V3s,n peptide were preincubated with the 
sera before addition to the plates (B). B/BO, binding obtained in the 
presence of ~m~titor~in~ng in the absence of competitor. 
not shown), and the corresponding avidity (K& from 
1 x 10m4 to 1 x 10m5 M: Fig. 6) were as low as to V3M,,. 
4. Discussion 
The glycans of gp160, which are almost equally di- 
vided into oligomannosidic and highly sialylated com- 
plex species [S] may influence its antigenicity. For exam- 
ple, antibodies elicited by gp160 whose mannose moieties 
are cleaved fail to neutralize HIV-l infection in contrast 
to antibodies raised against native or desialylated gp160 
[6,71. Interestingly, the latter antibodies recognize an oth- 
erwise silent conserved epitope downstram of gp120 V2 
loop, and they cross-react with HIV-2 gp140. 
It was then of interest o investigate whether siahc acid 
removal from gp 160,,, modifies the way antibodies rec- 
80 
m” 
zii60 
20 
-9 -8 -7 -6 -5 -4 
log[peptide] M 
* DliwMl 
* DVNYS 
* Dl/CDC4 
--f- ow 
- DaNY5 
+ D2/cOc4 
Fig. 6. ~te~ination of the avidity to V3 peptides from WMJZ, NY5 
and CDC4 isolates of sera raised against desialylated (Dl, D2) 
gp160,,. Conditions are as in Fig. 5. 
ognize V3, by exa~ning their cross-reactivity to V3 syn- 
thetic peptides from different HIV-l strains and their 
possible cross-neutralizing capacity for a relatively diver- 
gent strain such as HIV-lMIN. 
The top of the V3 loop comprises a conserved GPGR 
sequence shared by most isolates, which is flanked by 
variable aa residues. Several epitopes may be recognized 
by V3-specific NA, the binding of which requires either 
or both of GPGR flanking regions [X1,20,22,31]. 
Here, overlapping synthetic peptides were used to map 
the regions of V3 that were recognized by antibodies 
elicited against either desialylated or native gp160. All 
sera reacted with V3LAI (aa 307-327) and V3M1N (307- 
325) central region known to include the PND, which 
confirms its ~unodo~nan~. Peptides lacking aa res- 
idues flanking either or both sides of the GPGR tip did 
not attach antibodies, indicating that the corresponding 
aa are necessary for antibody recognition. 
When assayed against V3 peptides of different strains 
representative of American and European dominant iso- 
lates [ 141 all the sera also cross-reacted with the peptides 
derived from MN and SF2, which display about 65% 
homology with V3LAI, but not with those from more 
divergent SC, RF, or ELI, Z2 and 26 African strains. 
Interestingly, antibodies against desialylated gpl 60LAI 
reacted in addition with the V3 of WMJ2, CDC4 and 
NY5, which present about 50% homology with V3rAI. 
This tinding could be explained by the occurrence of a 
broadly reactive antibody population elicited by sialic 
acid removal from gp160,. One possibility is that desia- 
lylation induces conformational changes of gp160 that 
reveal structures that are common on the V3 of LAI, 
WMJ2, CDC4 and NY5. 
Such broad antibody binding ability might then be 
explained by the existence of epitopes within V3 that 
share homologies either in their primary or secondary 
structures. While the GPGR crown and the overall 
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length and charge are generally conserved among these 
peptides, their sequences present an important variabil- 
ity of the flanking aa residues. This presumably accounts 
for the different reactivity of the two sets of sera. There- 
fore, we analyzed these peptides by CD to investigate 
whether the observed reactivity pattern was actually re- 
lated to a common secondary structure. In line with what 
was previously reported for V3,N and V3un, [33], all 
peptides in aqueous solution showed similar spectra 
which were characteristic of predominantly random con- 
formations [32]. In TFE, all peptides tended to form 
a-helices. Thus, there is no obvious correlation between 
the antibody reactivity pattern and the secondary struc- 
ture of the peptides defined by CD. These results suggest 
that even though mutations, deletions and insertions 
may occur within V3, they do not significantly modify 
their flexibility. 
However, such analysis (% of homology, CD) does not 
address all the effects of individual aa changes. Indeed, 
antibody-antigen interactions depend on the mobility, 
packing density, shape, surface exposure and negative 
electrostatic potential of the epitope [34]. Thus, some aa 
contained within a sequence present a greater contribu- 
tion than others to the reactive epitope, and change of 
a single aa can be sufficient to completely abolish anti- 
body recognition. This has been verified for V3 [15,21- 
23,351. For example, change of P318 to Q almost com- 
pletely abolishes the binding and neutralizing activity of 
monoclonal antibody 0.5/I [21] and change of FR3** to 
L increases resistance to neutralization by soluble CD4 
[231. 
To assess whether the ability of sera to cross-react with 
divergent V3 peptides correlates with their capacity to 
neutralize the corresponding isolates, we studied their 
ability to inhibit syncytia induced by prototype HIV- 
1 While all sera inhibited syncytia mediated by HIV- 
1::‘ [6] only sera raised against native, but not those 
raised against desialylated gpl 60LAI, impaired HIV- 1 MN- 
induced syncytia. Because soluble V3 peptide efficiently 
abrogated the syncytium inhibitory effect of these sera, 
this indicates that we specifically adressed the anti-V3 
response in our assay. 
Because both types of sera recognized the same V3,, 
sequence, the discrepancy between the ability of Dl and 
D2 to additionally react to divergent V3 peptides but not 
to neutralize HIV-l ,,-mediated syncytia, cannot be ex- 
plained by differences due to antibodies recognizing dif- 
ferent epitopes. This may rather be related to the fact 
that their antibody titeres and avidity for V3MN were lo- 
and loo-fold lower, respectively, relative to Nl and N2. 
For example, when considering anti-V3 neutralizing 
human monoclonal antibodies ‘the higher the affinity for 
V3,, the less monoclonal antibody is needed to neutral- 
ize the virus’, and only antibodies with high affinities 
( < 1 x 10e6 M) are able to neutralize in vitro [15,31] or 
to apparently prevent HIV-I vertical transmission [36]. 
This may well apply to Dl and D2, whose K,,, was about 
1 x 10m5 M. Also, the avidity of these two sera for WMJ2, 
CDC4 and NY5 V3 peptides was low (K& > 10e5 M), 
which would indicate that they should fail to neutralize 
infection by these isolates in the same manner as they do 
for HIVMMN. 
Nevertheless, these results indicate that sialic acid sig- 
nificantly intluence V3 antigenicity. This may be surpris- 
ing if one considers the limited glycosylation of V3 as 
compared with other gp120 domains, all the more so that 
the only glycan in the loop has been determined as being 
of the high-mannose or hybrid type, and the former do 
not present sialic acids [8]. However, it is possible that 
the three closely located or other more distant complex- 
or hybrid-type glycans affect V3 immunological proper- 
ties. There is also other evidence for the direct role of 
glycans on V3 biological and immunological properties: 
(i) when considering vertical HIV transmission, ‘a con- 
served N-linked glycosylation site within the V3 region, 
present in each mother’s sequence set, was absent in all 
of the infant’s sequence set’ [37]; (ii) antibodies elicited 
by V3 peptide (301-315) failed to recognize gp120sr2 but 
not its unglycosylated counterpart [4]; (iii) resistance of 
HIV-l to neutralization was achieved by adding glycan 
in the V3 loop adjacent to the NA binding site [35]. 
Sialic acids have been reported to influence the confor- 
mation of glycoproteins in solution, especially through 
their negative charge that attracts electropositive basic 
aa to maintain the carbohydrate umbrella conformation 
[27-281, and this may prevent immune recognition by 
steric hindrance [38-391. As to positively charged V3, it 
is possible that sialic acid removal from close or distant 
glycans restores the glycan branch mobility, giving thus 
access to new epitopes. Such an effect has been suspected 
for CAEV [38], oversialylation of the envelope glycopro- 
teins of which may possible be responsible for the limited 
capacity of the virus to induce NA, whereas closely re- 
lated visna virus whose envelope is less sialylated can 
elicit efficient NA. 
Glycosylation, especially sialylation, may therefore 
play a role in modulating the protective immune re- 
sponse against HIV As noted here, desialylation im- 
proves the ability of sera to cross-react with V3 peptides 
of relatively divergent viral strains, but at the cost of 
avidity. Future studies should then aim at designing im- 
munization methods with abnormally glycosylated env 
productes in order to improve both the production and 
affinity of the resulting antibodies, in the hope to en- 
hance their neutralizing capacity. 
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